5
11, 2015
26
10, 2015
13
10, 2015
8
10, 2015
15
09, 2015
15
09, 2015
Valentina Guarneri et al., Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist
Diatech Pharmacogenetics2017-08-08T09:48:41+02:00
15
09, 2015
8
08, 2015
1
08, 2015
1
08, 2015